Sensitizing Staphylococcus aureus to antibacterial agents by decoding and blocking the lipid flippase MprF.
Christoph J SlavetinskyJanna N HauserCordula GekelerJessica SlavetinskyAndré GeyerAlexandra KrausDoris HeilingbrunnerSamuel WagnerMichael TesarBernhard KrismerSebastian KuhnChristoph M ErnstAndreas PeschelPublished in: eLife (2022)
The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. Multiple peptide resistance factor (MprF) is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that increases virulence and resistance of methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens to cationic host defense peptides and antibiotics. With the aim to design MprF inhibitors that could sensitize MRSA to antimicrobial agents and support the clearance of staphylococcal infections with minimal selection pressure, we developed MprF-targeting monoclonal antibodies, which bound and blocked the MprF flippase subunit. Antibody M-C7.1 targeted a specific loop in the flippase domain that proved to be exposed at both sides of the bacterial membrane, thereby enhancing the mechanistic understanding of bacterial lipid translocation. M-C7.1 rendered MRSA susceptible to host antimicrobial peptides and antibiotics such as daptomycin, and it impaired MRSA survival in human phagocytes. Thus, MprF inhibitors are recommended for new antivirulence approaches against MRSA and other bacterial pathogens.
Keyphrases
- methicillin resistant staphylococcus aureus
- staphylococcus aureus
- human health
- biofilm formation
- risk assessment
- endothelial cells
- fatty acid
- sars cov
- cancer therapy
- gram negative
- antimicrobial resistance
- coronavirus disease
- climate change
- drug delivery
- cystic fibrosis
- protein kinase
- induced pluripotent stem cells
- candida albicans